penetration of Meropenem in urine
Reading File
Finding Sources
Searching PubMed
meropenem urinary pharmacokinetics penetration
Searching the Web
meropenem urine penetration concentration pharmacokinetics renal excretion
Finding Sources
Finding Sources
Reading File
I now have comprehensive data from the FDA label, drug references, and textbooks. Here is a full, detailed answer:
Meropenem Urinary Penetration - Detailed Pharmacokinetics
Route of Elimination
Meropenem is primarily eliminated by the kidneys. Two mechanisms are involved:
- Glomerular filtration - passive filtration of unbound drug (protein binding is only ~2%, so virtually all circulating meropenem is free and filterable)
- Active tubular secretion - via OAT1 and OAT3 transporters in the proximal tubule (demonstrated by the fact that probenecid, an OAT inhibitor, increases meropenem AUC by ~56% and half-life by ~38%)
Urinary Recovery
| Fraction | Amount |
|---|---|
| Unchanged meropenem in urine (12 h) | ~70% (range 50-75%) |
| Microbiologically inactive ring-opened metabolite | ~28% |
| Fecal elimination | ~2% |
Total renal excretion accounts for ~98% of the administered dose.
Urinary Concentrations
After a 500 mg IV dose, peak urinary meropenem concentrations reach approximately 23 mcg/mL (range 14-26 mcg/mL). Critically, urine concentrations >10 mcg/mL are maintained for up to 5 hours after this dose. After a 1 g IV dose, peak urine concentrations rise to approximately 49 mcg/mL (range 39-58 mcg/mL).
These concentrations vastly exceed the MIC90 for most common uropathogens (e.g., E. coli, Klebsiella, Proteus - typically 0.016-0.5 mcg/mL for carbapenem-susceptible strains), making urine penetration clinically more than adequate.
Contrast with Imipenem
An important distinction: imipenem is rapidly hydrolyzed by renal tubular dehydropeptidase-1 (DHP-1), which degrades it in the renal tubule and significantly reduces its active urine concentrations. This is why imipenem must be co-administered with cilastatin (a DHP-1 inhibitor) to restore adequate urine levels. Meropenem, doripenem, and ertapenem are not significantly degraded by DHP-1 and therefore achieve high urinary concentrations without any inhibitor - an inherent pharmacokinetic advantage.
- Sherris & Ryan's Medical Microbiology, 8th Ed., p. 915
Renal Impairment
Because meropenem is so dependent on renal clearance, dose adjustment is required in renal impairment:
| CrCl (mL/min) | Half-life | Adjustment |
|---|---|---|
| >50 (normal) | ~1 hour | Standard dosing |
| 26-50 | ~1.9-3.3 h | Reduce dose or extend interval |
| 10-25 | ~3.8-5.7 h | Significant reduction required |
| <10 (or dialysis) | Markedly prolonged | Major dose reduction; supplement after HD |
In patients with reduced GFR, urinary concentrations will also be lower due to decreased filtration, but systemic concentrations rise - dosing is adjusted to avoid toxicity, not to compensate for reduced urinary penetration.
Drug Interaction Note
Co-administration with probenecid blocks tubular secretion, increasing systemic exposure by 56%. This combination is not recommended; it does not improve urinary concentrations (in fact, it reduces renal clearance and thus urinary delivery).
Clinical Implications
Meropenem's excellent urinary penetration makes it highly effective for:
- Complicated UTIs caused by ESBL-producing organisms
- Carbapenem-susceptible Pseudomonas aeruginosa UTIs
- Multidrug-resistant Enterobacterales urinary infections
The standard IV dose of 1 g q8h (or 500 mg q6h for uncomplicated UTI in some protocols) provides urine concentrations many times above the MIC for susceptible organisms throughout the dosing interval.
Sources: FDA MERREM IV Prescribing Information; Pfizer Meropenem Labeling; Sherris & Ryan's Medical Microbiology, 8th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.